SG11202111863RA - Bead-free ex-vivo expansion of human regulatory t cells - Google Patents

Bead-free ex-vivo expansion of human regulatory t cells

Info

Publication number
SG11202111863RA
SG11202111863RA SG11202111863RA SG11202111863RA SG11202111863RA SG 11202111863R A SG11202111863R A SG 11202111863RA SG 11202111863R A SG11202111863R A SG 11202111863RA SG 11202111863R A SG11202111863R A SG 11202111863RA SG 11202111863R A SG11202111863R A SG 11202111863RA
Authority
SG
Singapore
Prior art keywords
bead
cells
free
vivo expansion
human regulatory
Prior art date
Application number
SG11202111863RA
Other languages
English (en)
Inventor
Qizhi Tang
Nikolaos Skartsis
Flavio Vincenti
Original Assignee
Univ California
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Univ California filed Critical Univ California
Publication of SG11202111863RA publication Critical patent/SG11202111863RA/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
    • A61K35/14—Blood; Artificial blood
    • A61K35/17—Lymphocytes; B-cells; T-cells; Natural killer cells; Interferon-activated or cytokine-activated lymphocytes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/46—Cellular immunotherapy
    • A61K39/461—Cellular immunotherapy characterised by the cell type used
    • A61K39/4611—T-cells, e.g. tumor infiltrating lymphocytes [TIL], lymphokine-activated killer cells [LAK] or regulatory T cells [Treg]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/46—Cellular immunotherapy
    • A61K39/462—Cellular immunotherapy characterized by the effect or the function of the cells
    • A61K39/4621—Cellular immunotherapy characterized by the effect or the function of the cells immunosuppressive or immunotolerising
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/46—Cellular immunotherapy
    • A61K39/464—Cellular immunotherapy characterised by the antigen targeted or presented
    • A61K39/4643—Vertebrate antigens
    • A61K39/46433—Antigens related to auto-immune diseases; Preparations to induce self-tolerance
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/10—Processes for the isolation, preparation or purification of DNA or RNA
    • C12N15/1003—Extracting or separating nucleic acids from biological samples, e.g. pure separation or isolation methods; Conditions, buffers or apparatuses therefor
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/06—Animal cells or tissues; Human cells or tissues
    • C12N5/0602—Vertebrate cells
    • C12N5/0634—Cells from the blood or the immune system
    • C12N5/0636—T lymphocytes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/06—Animal cells or tissues; Human cells or tissues
    • C12N5/0602—Vertebrate cells
    • C12N5/0634—Cells from the blood or the immune system
    • C12N5/0636—T lymphocytes
    • C12N5/0637—Immunosuppressive T lymphocytes, e.g. regulatory T cells or Treg
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
    • A61K2035/124—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells the cells being hematopoietic, bone marrow derived or blood cells
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2501/00—Active agents used in cell culture processes, e.g. differentation
    • C12N2501/20—Cytokines; Chemokines
    • C12N2501/23—Interleukins [IL]
    • C12N2501/2301—Interleukin-1 (IL-1)
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2501/00—Active agents used in cell culture processes, e.g. differentation
    • C12N2501/20—Cytokines; Chemokines
    • C12N2501/23—Interleukins [IL]
    • C12N2501/2302—Interleukin-2 (IL-2)
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2501/00—Active agents used in cell culture processes, e.g. differentation
    • C12N2501/20—Cytokines; Chemokines
    • C12N2501/23—Interleukins [IL]
    • C12N2501/2306—Interleukin-6 (IL-6)
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2501/00—Active agents used in cell culture processes, e.g. differentation
    • C12N2501/20—Cytokines; Chemokines
    • C12N2501/24—Interferons [IFN]
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2501/00—Active agents used in cell culture processes, e.g. differentation
    • C12N2501/20—Cytokines; Chemokines
    • C12N2501/25—Tumour necrosing factors [TNF]
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2501/00—Active agents used in cell culture processes, e.g. differentation
    • C12N2501/50—Cell markers; Cell surface determinants
    • C12N2501/51—B7 molecules, e.g. CD80, CD86, CD28 (ligand), CD152 (ligand)
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2501/00—Active agents used in cell culture processes, e.g. differentation
    • C12N2501/998—Proteins not provided for elsewhere

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Biomedical Technology (AREA)
  • Cell Biology (AREA)
  • Organic Chemistry (AREA)
  • Microbiology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Zoology (AREA)
  • Biotechnology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Genetics & Genomics (AREA)
  • Wood Science & Technology (AREA)
  • Epidemiology (AREA)
  • Mycology (AREA)
  • General Engineering & Computer Science (AREA)
  • Hematology (AREA)
  • Biochemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Rheumatology (AREA)
  • Pain & Pain Management (AREA)
  • Developmental Biology & Embryology (AREA)
  • Virology (AREA)
  • Physics & Mathematics (AREA)
  • Plant Pathology (AREA)
  • Molecular Biology (AREA)
  • Biophysics (AREA)
  • Crystallography & Structural Chemistry (AREA)
  • Analytical Chemistry (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
SG11202111863RA 2019-04-30 2020-04-30 Bead-free ex-vivo expansion of human regulatory t cells SG11202111863RA (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201962841215P 2019-04-30 2019-04-30
PCT/US2020/030869 WO2020223568A1 (en) 2019-04-30 2020-04-30 Bead-free ex-vivo expansion of human regulatory t cells

Publications (1)

Publication Number Publication Date
SG11202111863RA true SG11202111863RA (en) 2021-11-29

Family

ID=73029279

Family Applications (1)

Application Number Title Priority Date Filing Date
SG11202111863RA SG11202111863RA (en) 2019-04-30 2020-04-30 Bead-free ex-vivo expansion of human regulatory t cells

Country Status (13)

Country Link
US (1) US20220204931A1 (ja)
EP (1) EP3963053A4 (ja)
JP (1) JP2022530768A (ja)
KR (1) KR20210149201A (ja)
CN (1) CN114008192A (ja)
AU (1) AU2020266599A1 (ja)
BR (1) BR112021021528A2 (ja)
CA (1) CA3137456A1 (ja)
CL (1) CL2021002849A1 (ja)
IL (1) IL287618A (ja)
MX (1) MX2021013227A (ja)
SG (1) SG11202111863RA (ja)
WO (1) WO2020223568A1 (ja)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP4438048A1 (en) * 2021-11-24 2024-10-02 Regcell Co., Ltd. Pharmaceutical composition for treating or preventing t cell-related disorders

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2014201846B2 (en) * 2007-01-30 2016-07-07 Epivax, Inc. Regulatory t cell epitopes, compositions and uses thereof
WO2012018930A1 (en) * 2010-08-03 2012-02-09 University Of Miami Methods of isolating and expanding human t regulatory cells and uses thereof for cellular therapy
US9481866B2 (en) * 2011-12-16 2016-11-01 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Methods of producing T cell populations enriched for stable regulatory T-cells
WO2013131045A1 (en) * 2012-03-02 2013-09-06 The Regents Of The University Of California Expansion of alloantigen-reactive regulatory t cells
EP2660250B1 (en) * 2012-05-02 2018-11-14 Deutsches Rheuma-Forschungszentrum Berlin Tcr transgenic mouse model for immune disease
PL218400B1 (pl) * 2012-06-06 2014-11-28 Gdański Univ Medyczny Szczepionka do leczenia cukrzycy typu 1 u dzieci, zastosowanie sortera komórek oraz sposób namnażania komórek Treg in vitro do wytwarzania szczepionki do leczenia cukrzycy typu 1
WO2014165581A1 (en) * 2013-04-02 2014-10-09 New York University Gpr15-mediated homing and uses thereof
WO2015198147A1 (en) * 2014-06-23 2015-12-30 Theramab Llc Compositions and methods for safe and effective immunotherapy
WO2016179288A1 (en) * 2015-05-04 2016-11-10 University Of Florida Research Foundation, Inc. Novel regulatory-cells, method for their isolation and uses
MX2018002849A (es) * 2015-09-07 2018-09-05 Inst Nat Sante Rech Med Una nueva subpoblacion de tregs cd8+cd45rcbajo y sus usos.

Also Published As

Publication number Publication date
CA3137456A1 (en) 2020-11-05
IL287618A (en) 2021-12-01
EP3963053A4 (en) 2023-01-18
BR112021021528A2 (pt) 2022-04-19
AU2020266599A1 (en) 2021-11-18
JP2022530768A (ja) 2022-07-01
MX2021013227A (es) 2022-01-06
EP3963053A1 (en) 2022-03-09
CL2021002849A1 (es) 2022-11-25
US20220204931A1 (en) 2022-06-30
KR20210149201A (ko) 2021-12-08
CN114008192A (zh) 2022-02-01
WO2020223568A1 (en) 2020-11-05

Similar Documents

Publication Publication Date Title
EP3589284A4 (en) USES OF PYRIMIDOPYRIMIDINONES AS SIK INHIBITORS
EP3768823A4 (en) METHODS OF USING ISLET CELLS
ZA202105970B (en) Novel heterotricyclic derivative compound and use of same
IL271159A (en) Synthesis of diastereomerically pure proteid phosphates
SG10202012352XA (en) Triesters of cyclohexanetripropionic acid
IL292676A (en) Generation of transgenic regulatory t cells
ZA201801503B (en) Formulation of a serum-free medium used for human pluripotent stem cells
EP3710021A4 (en) COMPOSITIONS FOR THE MANUFACTURE OF ISLAND CELLS AND METHODS OF USE
IL291622A (en) Compositions comprising regulatory t cells and methods of making and using them
EP4041386A4 (en) MOIST PREPARATION OF RADIATION THERAPY SOURCES
SG11202011191WA (en) Codon-optimized acid αlpha-glucosidase expression cassettes and methods of using same
IL276592A (en) History of Subtirum
HUE065045T2 (hu) Lanifibranor deuterált származékai
EP3651660A4 (en) STENTGRAFTS AND METHODS FOR INCREASING THE FLEXIBILITY OF STENTGRAFTS THROUGH THERMAL FOLDING
IL287618A (en) Droplet-free in vitro expansion of human regulatory t cells
SG11202103901YA (en) Expansion of hematopoietic stem cells
EP3362044A4 (en) TREATMENT AGAINST INFECTION COMPOSED OF MENSTRUAL BLOOD STEM CELLS
EP3942503A4 (en) MULTI-AXIS BLOCKCHAIN DELETION OF OFFERS
SG11202101671PA (en) Anti-lmp2 tcr-t cell therapy for the treatment of ebv-associated cancers
IL289376A (en) Methods and materials for directed expansion of regulatory t cells
PL3570661T3 (pl) Sposób uprawy grzybów
ZA202105399B (en) Use of spiropidion
GB201911056D0 (en) Treatment of ADD/ADHD
GB201817985D0 (en) Stem cell line for treatment of various medical conditions
EP4059077A4 (en) HEAT TREATMENT OF WHOLE-CELLULAR STRUCTURES